V
Vasilios Papademetriou
Researcher at Georgetown University
Publications - 352
Citations - 15150
Vasilios Papademetriou is an academic researcher from Georgetown University. The author has contributed to research in topics: Blood pressure & Left ventricular hypertrophy. The author has an hindex of 59, co-authored 348 publications receiving 14039 citations. Previous affiliations of Vasilios Papademetriou include University of Washington & Aristotle University of Thessaloniki.
Papers
More filters
Journal ArticleDOI
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
William C. Cushman,Charles E. Ford,Jeffrey A. Cutler,Karen L. Margolis,Barry R. Davis,Richard H. Grimm,Henry R. Black,Bruce P. Hamilton,Joanne Holland,Chuke Nwachuku,Vasilios Papademetriou,Jeffrey L. Probstfield,Jackson T. Wright,Michael H. Alderman,Robert J. Weiss,Linda B. Piller,Judy Bettencourt,Sandra M. Walsh +17 more
TL;DR: Blood pressure control rates for hypertension fall far short of the US national goal of 50% or more, but achievable control rates in varied practice settings and geographic regions are not well identified.
Journal ArticleDOI
Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
Sander J. Robins,Dorothea Collins,Janet Wittes,Vasilios Papademetriou,Prakash Deedwania,Ernst J. Schaefer,Judith R. McNamara,Moti L. Kashyap,Jerome M. Hershman,Laura F. Wexler,Hanna Bloomfield Rubins +10 more
TL;DR: Concentrations of LDL-C achieved with gemfibrozil treatment predicted a significant reduction in CHD events in patients with low HDL-C levels, however, the change in HDL- C levels only partially explained the beneficial effect of gem fibroZil.
Journal ArticleDOI
Prognostic significance of left ventricular mass change during treatment of hypertension
Richard B. Devereux,Kristian Wachtell,Eva Gerdts,Krister K. Boman,Markku S. Nieminen,Vasilios Papademetriou,Jens Rokkedal,Katherine E. Harris,Peter Aurup,Björn Dahlöf +9 more
TL;DR: In patients with essential hypertension and baseline electrocardiographic LV hypertrophy, lower LV mass during antihypertensive treatment is associated with lower rates of clinical end points, additional to effects of blood pressure lowering and treatment modality.
Journal ArticleDOI
Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial
Richard B. Devereux,Björn Dahlöf,Eva Gerdts,Kurt Boman,Markku S. Nieminen,Vasilios Papademetriou,Jens Rokkedal,Katherine E. Harris,Jonathan M. Edelman,Kristian Wachtell +9 more
TL;DR: Antihypertensive treatment with losartan, plus hydrochlorothiazide and other medications when needed for pressure control, resulted in greater LVH regression in patients with ECG LVH than conventional atenolol-based treatment, indicating angiotensin receptor antagonism byLosartan has superior efficacy for reversing LVH, a cardinal manifestation of hypertensive target organ damage.
Journal ArticleDOI
Exercise Capacity and Mortality in Black and White Men
Peter Kokkinos,Jonathan Myers,John Peter Kokkinos,Andreas Pittaras,Puneet Narayan,Athanasios Manolis,Pamela Karasik,Michael Greenberg,Vasilios Papademetriou,Steven N. Singh +9 more
TL;DR: The relationship was inverse and graded, with a similar impact on mortality outcomes for both blacks and whites, and exercise capacity was the strongest predictor of risk for mortality.